argenx SE (ARGNF)
| Market Cap | 52.36B |
| Revenue (ttm) | 3.68B |
| Net Income (ttm) | 1.53B |
| Shares Out | n/a |
| EPS (ttm) | 23.27 |
| PE Ratio | 34.15 |
| Forward PE | 29.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 108 |
| Average Volume | 13 |
| Open | 870.00 |
| Previous Close | 872.27 |
| Day's Range | 870.00 - 870.00 |
| 52-Week Range | 532.40 - 872.27 |
| Beta | -0.11 |
| RSI | 72.38 |
| Earnings Date | Mar 5, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]
Financial Performance
Financial StatementsNews
Argenx (ARGX) Ends Study of Efgartigimod for Thyroid Eye Disease
Argenx (ARGX) Ends Study of Efgartigimod for Thyroid Eye Disease
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
Argenx discontinues its Phase 3 UplighTED trial in ... Full story available on Benzinga.com
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
Argenx SE (NASDAQ: ARGX) on Monday announced it would discontinue the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with mode...
Argenx Flops, As Viridian Celebrates, On Surprise Setback For Vyvgart Powerhouse
Argenx stock toppled Monday after the biotech scrapped plans to develop its blockbuster drug, Vyvgart, for thyroid eye disease.
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Monday. Shares of argenx SE – ADR (NASDAQ: ARGX) fell sharply in pre-market trading after the company di...
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Monday.
Argenx (ARGX) Halts Phase 3 Trials for Thyroid Eye Disease Treatment
Argenx (ARGX) Halts Phase 3 Trials for Thyroid Eye Disease Treatment
Argenx To Discontinue UplighTED Studies In Thyroid Eye Disease Due To Futility
(RTTNews) - Argenx SE (ARGX ARGX.BR) announced on Monday that it is discontinuing its Phase 3 UplighTED studies evaluating Efgartigimod PH20 SC in adults with moderate to severe thyroid eye disease, b...
argenx to discontinue phase 3 UplighTED trials of efgartigimod in thyroid eye disease; stock drops
Stock Market Today: Dow Futures, S&P 500 Advance Ahead Of Key Economic Data: iRobot, Argenx, MindWalk In Focus
U.S. stock futures are up early Monday morning, following a mixed week that saw rotation out of expensive tech stocks in favor of value, despite the third consecutive interest rate cut on Wednesday. I...
Stock Market Today: Dow Futures, S&P 500 Advance Ahead Of Key Economic Data: iRobot, Argenx, MindWalk In Focus
U.S. stock futures are up early Monday morning, following a mixed week that saw rotation out of expensive tech stocks in favor of value, despite the third consecutive interest rate cut on Wednesday.
Argenx, Navan And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects MindWalk Holdings Corp. (NASDAQ: HYFT) to repo...
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
KROS vs. ARGX: Which Stock Is the Better Value Option?
KROS vs. ARGX: Which Stock Is the Better Value Option?
Wells Fargo Raises Price Target for ARGX, Maintains Overweight Rating | ARGX Stock News
Wells Fargo Raises Price Target for ARGX, Maintains Overweight Rating | ARGX Stock News
ARGX: Stifel Raises Price Target While Maintaining Buy Rating | ARGX Stock News
ARGX: Stifel Raises Price Target While Maintaining Buy Rating | ARGX Stock News
ARGX: JP Morgan Raises Price Target, Maintains Overweight Rating | ARGX Stock News
ARGX: JP Morgan Raises Price Target, Maintains Overweight Rating | ARGX Stock News
ARGX: Morgan Stanley Raises Price Target to $1110, Maintains Overweight Rating | ARGX Stock News
ARGX: Morgan Stanley Raises Price Target to $1110, Maintains Overweight Rating | ARGX Stock News
ARGX Quantitative Stock Analysis - Benjamin Graham
Below is Validea's guru fundamental report for ARGENX SE - ADR (ARGX). Of the 22 guru strategies we follow, ARGX rates highest using our Value Investor model based on the published strategy of Benjami...
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 12.46% on an annualized basis producing an average annual return of 25.71%. Currently, argenx has a market capitalization of...
Looking Into argenx SE's Recent Short Interest
argenx SE's (NYSE: ARGX) short interest as a percent of float has fallen 8.96% since its last report. According to exchange reported data, there are now 1.70 million shares sold short , which is 3.05...
argenx: Sights Set On $1,000
argenx continues to outperform expectations, driven by Vyvgart's strong commercial momentum and impressive growth in CIDP and gMG markets. Vyvgart is on track to deliver more than $4.1 billion in net ...
This Argenx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
ARGX Downgraded by Wolfe Research to 'Peer Perform' | ARGX Stock News
ARGX Downgraded by Wolfe Research to 'Peer Perform' | ARGX Stock News
Guru Fundamental Report for ARGX - Benjamin Graham
Below is Validea's guru fundamental report for ARGENX SE - ADR (ARGX). Of the 22 guru strategies we follow, ARGX rates highest using our Value Investor model based on the published strategy of Benjami...